Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
Charles Andrew Butts, Mark A. Socinski, Paul L R Mitchell et al. · The Lancet Oncology · 2013
Cited by 538 works. doi:10.1016/s1470-2045(13)70510-2
Authors
- Charles Andrew Butts
- Mark A. Socinski
- Paul L R Mitchell
- N. Thatcher
- Libor Havel
- Maciej Jerzy Krzakowski
- Sergiusz Nawrocki
- Tudor–Eliade Ciuleanu
- Lionel Bosquée
- José Manuel Trigo
- Alexander I. Spira
- Lise Tremblay
- Jan Nyman
- Rodryg Ramlau
- Gun Wickart-Johansson
- Oleg A. Gladkov
- José Rodrigues Pereira
- Wilfried Eberhardt
- Christoph Helwig
References
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
- Mucins in cancer: protection and control of the cell surface
- Phase III Study of Cisplatin, Etoposide, and Concurrent Chest Radiation With or Without Consolidation Docetaxel in Patients With Inoperable Stage III Non–Small-Cell Lung Cancer: The Hoosier Oncology Group and U.S. Oncology
- Quality of life assessment in individuals with lung cancer: Testing the Lung Cancer Symptom Scale (LCSS)
- Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small-Cell Lung Cancer: SWOG S0023
- The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
- Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
- Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- Randomized Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non–Small-Cell Lung Cancer